Drug profile · INN
levodopa
CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)
- US status
- approved
- Patents linked
- 8
- News articles
- 0
Quick answer
levodopa (CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 12370163
Levodopa dosing regimen
granted -
US 12303482
Levodopa dosing regimen
granted -
US 12303481
Levodopa dosing regimen
granted -
US 12295931
Levodopa dosing regimen
granted -
US 12263148
Levodopa dosing regimen
granted -
US 12263149
Levodopa dosing regimen
granted -
US 12201596
Levodopa dosing regimen
granted -
US 12194150
Levodopa dosing regimen
granted
Frequently asked questions
What is levodopa?
levodopa (CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for levodopa?
CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ) is a marketed brand name for levodopa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levodopa?
levodopa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.